newsfilter
← Latest News
GlobeNewswire·

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.Sepranolone IND filing